These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 34730477)
1. Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States. Exuzides A; Reddy SR; Chang E; Ta JT; Patel AM; Paydar C; Yohrling GJ J Med Econ; 2021; 24(1):1327-1336. PubMed ID: 34730477 [TBL] [Abstract][Full Text] [Related]
2. Healthcare utilization and direct medical costs of Huntington's disease among Medicaid beneficiaries in the United States. Patel AM; Chang E; Paydar C; Reddy SR J Med Econ; 2023; 26(1):811-820. PubMed ID: 37285853 [TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population. Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039 [TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study. To TM; Ta JT; Patel AM; Arndorfer S; Abbass IM; Gandhy R J Med Econ; 2023; 26(1):862-870. PubMed ID: 37350423 [TBL] [Abstract][Full Text] [Related]
5. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population. To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937 [No Abstract] [Full Text] [Related]
6. Inpatient Utilization and Costs for Medicare Fee-for-Service Beneficiaries with Heart Failure. Fitch K; Pelizzari PM; Pyenson B Am Health Drug Benefits; 2016 Apr; 9(2):96-104. PubMed ID: 27182428 [TBL] [Abstract][Full Text] [Related]
7. Nonoperative care to manage sacroiliac joint disruption and degenerative sacroiliitis: high costs and medical resource utilization in the United States Medicare population. Ackerman SJ; Polly DW; Knight T; Holt T; Cummings J J Neurosurg Spine; 2014 Apr; 20(4):354-63. PubMed ID: 24527824 [TBL] [Abstract][Full Text] [Related]
8. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis. Divino V; Dekoven M; Warner JH; Giuliano J; Anderson KE; Langbehn D; Lee WC J Med Econ; 2013 Aug; 16(8):1043-50. PubMed ID: 23789925 [TBL] [Abstract][Full Text] [Related]
9. The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning. Roland CL; Ye X; Stevens V; Oderda GM J Manag Care Spec Pharm; 2019 Jan; 25(1):18-27. PubMed ID: 30589633 [TBL] [Abstract][Full Text] [Related]
10. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States. Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250 [TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Huntington's Disease in the United States Medicare and Medicaid Populations. Exuzides A; Reddy SR; Chang E; Ta JT; Patel AM; Paydar C; Yohrling GJ Neuroepidemiology; 2022; 56(3):192-200. PubMed ID: 35483335 [TBL] [Abstract][Full Text] [Related]
12. Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antivirals. Best JH; Reddy SR; Chang E; Bognar K; Tarbox MH; Cagas SE; Seetasith A J Med Econ; 2024; 27(1):240-252. PubMed ID: 38294309 [TBL] [Abstract][Full Text] [Related]
13. The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings. Neuenschwander JF; Silverstein AR; Teigland CL; Kumar S; Zeng EY; Agiro AT; Pottorf WJ; Peacock WF Adv Ther; 2023 Mar; 40(3):1204-1223. PubMed ID: 36652174 [TBL] [Abstract][Full Text] [Related]
14. Cost savings for pVAD compared to ECMO in the management of acute myocardial infarction complicated by cardiogenic shock: An episode-of-care analysis. Vetrovec GW; Lim MJ; Needham KA Catheter Cardiovasc Interv; 2021 Oct; 98(4):703-710. PubMed ID: 32790231 [TBL] [Abstract][Full Text] [Related]
15. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia. Lee TY; Johnson A; Cooke CE; Yared JA; Summers A; Yang K; Liu S; Tang B; Onukwugha E J Manag Care Spec Pharm; 2024 May; 30(5):430-440. PubMed ID: 38701030 [TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144 [TBL] [Abstract][Full Text] [Related]
17. Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. Li P; Benson C; Geng Z; Seo S; Patel C; Doshi JA J Med Econ; 2023; 26(1):525-536. PubMed ID: 36961119 [TBL] [Abstract][Full Text] [Related]
18. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447 [TBL] [Abstract][Full Text] [Related]
19. Epidemiology and economic burden of Huntington's disease: a Canadian provincial public health system perspective. Shaw E; Mayer M; Ekwaru P; McMullen S; Graves E; Wu JW; Budd N; Maturi B; Cowling T; Mestre TA J Med Econ; 2022; 25(1):212-219. PubMed ID: 35073826 [TBL] [Abstract][Full Text] [Related]
20. The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington's disease. Kim H; Serbin M; Hansen R; Lee K; Haubenberger D; Klepitskaya O; Hinton SC; Jen E J Med Econ; 2024; 27(1):1348-1357. PubMed ID: 39373538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]